Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Way to Business: Startup Illustrations Learned - 2AfD in Brandenburg takes back suit against the intelligence service
- 3Vote In favor of Your Number one Savvy Beds
- 4Atorvastatin recall may affect hundreds of thousands of patients – and reflects FDA’s troubles inspecting medicines manufactured overseas
- 5Getting ready for a Mechanized World: 10 Positions That computer based intelligence Could Dominate
- 5 Signs Now is the ideal time to Update Your Android Telephone: When to Take the Action
- Investigating Design and Individual Style: Track down Your Remarkable Look
- Building Tough Connections: Individual Bits of knowledge on Association
- 2024's Savvy Home Gadgets for an Associated Way of life
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
- A definitive Bike Standoff: Decision in favor of Your Number one Ride
- Israeli president concerned over proposed renaming of park
- 4 Creative Savvy Home Gadgets of 2024: Reforming Home Robotization and Security
- An Extended period of Voyaging Carefully: the World with Reason
